Brain-Type Creatine Kinase Release from Cultured Osteoclasts Exposed to Neridronate in Children Affected by Osteogenesis Imperfecta Type 1
Authors:
- Maria Felicia FaienzaMaria Felicia Faienza
- Albina TummoloATAlbina Tummolo
- Mauro CelliMCMauro Celli
- Roberto FinocchiaroRFRoberto Finocchiaro
- Laura PiacenteLPLaura Piacente
- Francesca Di SerioFSFrancesca Di Serio
- Grazia Paola NicchiaGNGrazia Paola Nicchia
- Giacomina BrunettiGBGiacomina Brunetti
- Patrizia D’eufemiaPDPatrizia D’eufemia
Open Access
- 4 February 2023
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 11 (2) , 458
Abstract
Brain-type creatine kinase (CK-BB) increases during osteoclastogenesis, with high circulating amounts in type I osteogenesis imperfecta (OI) following treatment with neridronate, a bisphosphonate able to inhibit osteoclast activity and survival. The aim of this study was to demonstrate the correlation between osteoclastogenesis and CK-BB release from OI patients’ osteoclasts treated with different concentrations of neridronate. Our patients showed reduced bone quality, increased levels of CTX I, a marker of bone resorption, and decreased levels of OPG, an inhibitor of osteoclastogenesis. In OI patients, the presence of MCSF and RANKL determined an increased secretion of CK-BB from osteoclasts (p = 0.04) compared with control conditions without these cytokines; interestingly, in the absence of these factors, the secretion of CK-BB is significantly elevated at 3 µmol/L compared with 0.03 and 1 µmol/L (p = 0.007). In healthy donors’ cultures, the higher concentration of CK-BB can be detected following stimulation with 3 µmol/L neridronate compared with the untreated condition both with and without MCSF and RANKL (p = 0.03 and p = 0.006, respectively). Consistently, in osteoclast cultures, neridronate treatment is associated with a decrease in multinucleated TRAP+ cells, together with morphology changes typical of apoptosis. Consistently, in the media of the same osteoclast cultures, we demonstrated a significant increase in caspase-3 levels. In conclusion, our findings support the idea that CK-BB levels increase in the serum of OI-treated patients.Keywords
This publication has 40 references indexed in Scilit:
- Efficacy and safety of monthly oral minodronate in patients with involutional osteoporosisOsteoporosis International, 2011
- The creatine kinase system and pleiotropic effects of creatineAmino Acids, 2011
- The effects of estrogen receptors α‐ and β‐specific agonists and antagonists on cell proliferation and energy metabolism in human bone cell lineJournal of Cellular Biochemistry, 2010
- RANKL Up-regulates Brain-type Creatine Kinase via Poly(ADP-ribose) Polymerase-1 during OsteoclastogenesisJournal of Biological Chemistry, 2010
- Immature Osteoblast Lineage Cells Increase Osteoclastogenesis in Osteogenesis Imperfecta MurineThe American Journal of Pathology, 2010
- Cellular Mechanism of Decreased Bone in Brtl Mouse Model of OI: Imbalance of Decreased Osteoblast Function and Increased Osteoclasts and Their PrecursorsJournal of Bone and Mineral Research, 2008
- Increased resorptive activity and accompanying morphological alterations in osteoclasts derived from the oim/oim mouse model of osteogenesis imperfectaJournal of Cellular Biochemistry, 2007
- Osteoclast molecular phenotyping by random cDNA sequencingBone, 1995
- Elevated Levels of Creatine Kinase BB Isoenzyme in Three Patients with Adult OsteopetrosisNew England Journal of Medicine, 1989
- Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty.Archives of Disease in Childhood, 1976